ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2613

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients

Lavanya Mittal1, Lingqiao Zhang2, Rui Feng2 and Victoria Werth1, 1Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antimalarial drugs, Cutaneous lupus erythematosus, dermatomyositis, drug toxicity and hydroxychloroquine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may soon become increasingly difficult to prescribe as a result of these concerns. We investigate the toxicity risk associated with various antimalarial combinations in rheumatic skin disease patients.

Methods: 532 patients (mean age=52.29 years, female=85.15%, male=14.85%) were selected from two ongoing databases of cutaneous lupus erythematosus (69.92%) and dermatomyositis (30.08%). Details regarding antimalarial treatment and toxicities were extracted and five different treatment courses were defined [i.e., hydroxychloroquine, chloroquine, and quinacrine monotherapies, as well as hydroxychloroquine+quinacrine and chloroquine+quinacrine combinations]. The hazard ratio of each major toxicity on the five different treatment courses was estimated using the Cox proportional hazard model to compare the risk associated with each type of treatment to that of hydroxychloroquine.

Results:

Over 90% of patients had a history of hydroxychloroquine, and nearly half (42.9%) had a history of hydroxychloroquine+quinacrine. Only 21.3% of patients had a history of chloroquine either as monotherapy (11.1%) or as chloroquine+quinacrine combination (10.2%). Over half of the patients had a history of quinacrine, usually in combination with hydroxychloroquine or chloroquine, but also as monotherapy (11.8%).

The most prevalent side effects included cutaneous eruption (n=61), gastrointestinal upset (n=38), mucocutaneous dyspigmentation (n=26), neurologic toxicities [i.e., including dizziness and headache (n=10), ototoxicity (n=5), sleep disturbances (n=5), mental fog (n=5), peripheral neuropathy (n=4), tremors (n=2), and psychosis (n=1)], and retinopathy (n=17). Compared to hydroxychloroquine, the hazards of cutaneous eruption, gastrointestinal upset, and neurologic toxicities were lower with hydroxychloroquine+quinacrine. However, based on a post-hoc analysis, this may represent the selection of patients able to tolerate hydroxychloroquine in the cohort of those who received hydroxychloroquine+quinacrine. Although there was increased risk of retinopathy with chloroquine and chloroquine+quinacrine relative to hydroxychloroquine, ophthalmic toxicity was not seen with quinacrine (Table I).

Conclusion: Our study provides evidence that the safety profile of quinacrine is comparable to that of first-line hydroxychloroquine and that quinacrine has an advantage over hydroxychloroquine and chloroquine for patients at risk of retinopathy. Furthermore, adding quinacrine to hydroxychloroquine or chloroquine does not increase the risk of toxicities, and limiting access to quinacrine may leave patients without alternatives to this safe drug.

Table I.

Treatment Course

Adjusted HRa

95% Confidence Interval for Adjusted HR

Un-adjusted HR

95% Confidence Interval for Un-adjusted HR

Chloroquine

Skin Eruption

0.277

0.038-2.028

0.563

0.135-2.341

Dyspigmentation

†

†

GI Upset

0.400

0.054-2.961

0.354

0.048-2.606

Neurologic

†

†

Ophthalmic

30.349 ****

2.588-355.887

12.880 **

1.789-92.723

Quinacrine

Skin Eruption

†

†

Dyspigmentation

4.047

0.956-17.139

3.278

0.787-13.646

GI Upset

1.273

0.380-4.266

1.028

0.312-3.388

Neurologic

0.459

0.061-3.461

0.455

0.061-3.386

Ophthalmic

†

†

HCQ+Quinacrine

Skin Eruption

0.231 ****

0.082-0.651

0.236 ****

0.084-0.664

Dyspigmentation

1.517

0.485-4.746

1.416

0.462-4.343

GI Upset

0.260 **

0.078-0.863

0.227 **

0.069-0.747

Neurologic

0.195 **

0.045-0.840

0.199 **

0.047-0.845

Ophthalmic

2.248

0.136-37.028

1.152

1.104-12.753

CQ+Quinacrine

Skin Eruption

0.849

0.260-2.771

0.865

0.266-2.812

Dyspigmentation

1.299

0.160-10.529

1.234

0.154-9.878

GI Upset

0.446

0.060-3.314

0.170

3.001

Neurologic

0.471

0.063-3.519

0.451

0.061-3.345

Ophthalmic

26.664 ****

2.723-261.101

13.578 ****

2.261-81.548

HCQ = hydroxychloroquine; CQ = chloroquine; HCQ+Quinacrine = hydroxychloroquine+quinacrine; CQ+Q = chloroquine+quinacrine

a = Cox proportional hazard ratios (HR) of toxicities while on various antimalarial regimens, with risk of toxicities on hydroxychloroquine monotherapy as the reference level; adjusted for sex, age, race, and smoking status (never vs. current and past smokers)

** P < 0.05

**** P < 0.01

† = No observations of toxicity


Disclosure: L. Mittal, None; L. Zhang, None; R. Feng, None; V. Werth, None.

To cite this abstract in AMA style:

Mittal L, Zhang L, Feng R, Werth V. Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/antimalarial-drug-toxicities-in-rheumatic-skin-disease-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antimalarial-drug-toxicities-in-rheumatic-skin-disease-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology